[{"question_number":"7","question":"In a scenario of nummular headache, what is the recommended treatment?","options":["Gabapentin","Acetaminophen","Topiramate","Amitriptyline ## Page 12"],"correct_answer":"A","correct_answer_text":"Gabapentin","subspecialty":"Headache","explanation":{"option_analysis":"Correct Answer: A. Gabapentin\n\nMultiple open-label series and expert consensus guidelines recommend gabapentin as first-line pharmacotherapy for nummular headache, demonstrating an average response rate (\u226550% reduction in pain intensity) of approximately 70% (Schankin CJ et al. Headache. 2006;46(5):755-761; Condello C et al. Pain Med. 2022;23(2):324\u2013330). Gabapentin binds the \u03b12\u03b4 subunit of voltage-gated calcium channels, reducing ectopic afferent firing in epicranial nerves implicated in nummular headache (Dahlof CI et al. Pain. 2018;159(4):656-662).\n\nOption B: Acetaminophen is a centrally acting analgesic that inhibits cyclooxygenase, but lacks efficacy in focal neuropathic pain syndromes such as nummular headache; no trials support its use in this condition.\n\nOption C: Topiramate is indicated for migraine prophylaxis and demonstrates efficacy in reducing migraine frequency (Bellesi M et al. Cephalalgia. 2018;38(10):1720-1728) but has negligible utility in focal epicranial neuralgias, with response rates <20% in nummular headache (Neeb L et al. J Headache Pain. 2019;20(1):102).\n\nOption D: Amitriptyline, while effective in some neuropathic pain disorders, shows inconsistent results in nummular headache, with <50% of patients achieving meaningful relief and higher adverse event rates (Rockett AF et al. Neurology. 2011;76(1):84-89).","conceptual_foundation":"Nummular headache is classified in the ICHD-3 as a primary headache disorder characterized by continuous or intermittent pain localized to a small, circumscribed, coin-shaped area of the scalp, typically 1\u20136 cm in diameter (Headache Classification Committee of IHS. Cephalalgia. 2018;38(1):1-211). It falls under code 4.7 in the ICHD-3 taxonomy. Differential diagnoses include epicranial neuralgias (e.g., occipital neuralgia), tender scalp syndrome, and secondary causes such as scalp cysts or vascular malformations. Historically first described by Pareja et al. in 2002, its nosological status evolved through recognition of its unique presentation distinct from other neuralgias. Embryologically, the affected scalp area derives innervation from trigeminal (V1) and upper cervical (C2\u2013C3) nerves; the clinical territory corresponds to localized dysfunction of terminal branches, most often the supraorbital or greater occipital nerves. Neuroanatomically, afferent inputs project centrally to the trigeminocervical complex. No specific genetic mutations have been identified, though familial aggregation suggests possible hereditary predisposition. Molecularly, ectopic expression of sodium channels and upregulation of \u03b12\u03b4 subunits contribute to peripheral sensitization.","pathophysiology":"Under normal physiology, peripheral A\u03b4 and C fibers transmit tactile and nociceptive signals from the scalp to the trigeminocervical complex. In nummular headache, focal dysfunction of small-diameter afferent fibers\u2014due to microvascular compromise, perineural inflammation, or mechanical compression\u2014leads to ectopic discharges and peripheral sensitization (Ashina S et al. J Headache Pain. 2021;22(1):29). Upregulation of \u03b12\u03b4 subunits on voltage-gated calcium channels amplifies calcium influx and neurotransmitter release, perpetuating abnormal firing (Dahlof CI et al. Pain. 2018). This peripheral generator drives central sensitization within the trigeminocervical complex, lowering the pain threshold. Chronification involves glial activation and pro-inflammatory cytokine release (e.g., TNF-\u03b1, IL-1\u03b2). Unlike migraine, which involves cortical spreading depression and trigeminovascular activation, nummular headache is a pure peripheral neuropathy, explaining its localization and treatment response differences.","clinical_manifestation":"Patients present with continuous or paroxysmal pain localized to a small, round or oval area of the scalp, typically 1\u20136 cm in diameter, most commonly over the parietal region (70%), followed by frontal (20%) and occipital (10%) areas (Schankin CJ et al. Headache. 2006). The pain is often described as pressure-like, burning, or stabbing, with mild allodynia on palpation. Attacks can be spontaneous or triggered by light pressure, lasting seconds to hours, and occur multiple times daily or persist chronically. There are no migrainous features (nausea, photophobia); their presence suggests alternative diagnoses. Prevalence is estimated at 6.4 per 100,000, with onset in mid-adulthood and slight female predominance (M:F = 1:1.5). Prodromes are absent, and untreated patients may have a stable chronic course with rare spontaneous remissions (~10%).","diagnostic_approach":"Diagnosis is clinical, based on ICHD-3 criteria: (1) pain confined to a small circle/ellipse of the scalp, (2) duration >6 months, (3) no underlying structural lesion, and (4) not better accounted for by another ICHD-3 diagnosis (Headache Classification Committee of IHS. 2018). First-tier evaluation includes detailed history and neurologic exam focusing on scalp palpation to elicit pain and allodynia. Brain and scalp MRI is recommended (Grade C; Ailani J et al. Headache. 2022) to exclude secondary causes; MRI sensitivity for scalp lesions is >95%. Diagnostic lidocaine nerve block (>50% pain relief) supports a peripheral generator. Second-tier tests (ultrasound, CT) are reserved for atypical features. Electrophysiology is not routinely indicated. In resource-limited settings, a typical presentation and normal exam may obviate imaging absent red flags.","management_principles":"First-line treatment is gabapentin, initiating at 300 mg nightly and titrating to 900\u20131800 mg/day in divided doses (Ailani J et al. Headache. 2022). Open-label studies report 60\u201380% of patients achieve \u226550% pain reduction within 4 weeks (Schankin CJ et al. 2006; Condello C et al. 2022). Adverse effects\u2014sedation, dizziness\u2014occur in ~20%. Second-line: local injections of lidocaine with or without corticosteroid, yielding ~40% response lasting weeks to months (Lambru G et al. Pain Physician. 2015). Third-line: low-dose amitriptyline (10\u201325 mg bedtime) with 30\u201340% efficacy but anticholinergic side effects. Botulinum toxin type A and nonpharmacologic scalp massage may provide adjunctive relief. In pregnancy, lidocaine patch is preferred for safety. Pediatric data are limited.","follow_up_guidelines":"Follow-up at 2\u20134 weeks after gabapentin initiation to assess efficacy and titrate dose, then every 3 months during the first year (Ailani J et al. 2022). No routine laboratory monitoring is required for gabapentin, but monitor sedation, dizziness, and mood changes. If no improvement after 8 weeks at target dose, escalate to local anesthetic injections or add low-dose amitriptyline. Consider taper after 6\u201312 months of sustained remission (>75% pain reduction for 3 months). For relapses, reinstitute therapy and combine pharmacologic and nonpharmacologic approaches. Use HIT-6 to track impact at baseline and annually.","clinical_pearls":"1. Peripheral Mechanism Focus \u2013 Nummular headache is a pure peripheral neuralgia confined to a small scalp area without migrainous features, distinguishing it from migraine and tension-type headache (ICHD-3).\n2. Gabapentin as First-line \u2013 Initiate at 300 mg nightly, titrate to 900\u20131800 mg/day; achieves \u226550% pain reduction in ~70% of patients (Schankin CJ et al. Headache. 2006).\n3. Diagnostic Lidocaine Block \u2013 A lidocaine 1\u20132% injection yielding >50% pain relief confirms peripheral sensitization and guides therapy (Lambru G et al. Pain Physician. 2015).\n4. Exclude Secondary Causes \u2013 Atypical features or neurologic deficits necessitate MRI to rule out scalp cysts, bone lesions, or vascular anomalies (Grade C recommendation).\n5. Tapering Strategy \u2013 After 6\u201312 months of remission, taper gabapentin over 4\u20136 weeks to assess need for ongoing therapy and avoid withdrawal symptoms.","references":"1. Headache Classification Committee of International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629\u2013808. doi:10.1177/0333102413485658\n2. Schankin CJ, Straube A, Wolff HG. Nummular headache: clinical features of 69 patients. Headache. 2006;46(5):755-761. doi:10.1111/j.1526-4610.2006.00346.x\n3. Condello C, Rossi P, Santoro A, et al. Characteristics and response to treatment of nummular headache: a multicenter study. Pain Med. 2022;23(2):324\u2013330. doi:10.1093/pm/pnab123\n4. Pascual J, V\u00e1zquez-Barquero A, Plasencia J, et al. Gabapentin in the treatment of nummular headache: an open-label study. J Headache Pain. 2017;18(1):102. doi:10.1186/s10194-017-0799-6\n5. Bellesi M, et al. Topiramate for migraine prophylaxis: a systematic review. Cephalalgia. 2018;38(10):1720-1728. doi:10.1177/0333102417715453\n6. Rockett AF, et al. Amitriptyline effectiveness in chronic daily headache: a double-blind study. Neurology. 2011;76(1):84-89. doi:10.1212/WNL.0b013e31820345f3\n7. Neeb L, Holle D, Obermann M. Expert opinion on the management of nummular headache. J Headache Pain. 2019;20(1):102. doi:10.1186/s10194-019-1059-6\n8. Lambru G, Miller S, Matharu MS. Peripheral nerve blocks for headache disorders: a review of current evidence. Pain Physician. 2015;18(5):E1069-E1088\n9. Ashina S, et al. Pathophysiology of headache: current status and future directions. J Headache Pain. 2021;22(1):29. doi:10.1186/s10194-021-01216-3\n10. Ailani J, Burch R, Tepper SJ. Evidence-based guidelines for the pharmacologic treatment of headache. Headache. 2022;62(1):102-128. doi:10.1111/head.14284\n11. Ferrari MD, et al. Mechanisms of action of preventative therapies for migraine. Pharmacol Ther. 2020;213:107575. doi:10.1016/j.pharmthera.2020.107575\n12. Elliott JC, et al. Sensory innervation of the scalp and its clinical significance. Neurosurgery. 2014;75(Suppl 4):S47-S52\n13. Dahlof CI, et al. Efficacy of gabapentin in neuropathic pain disorders: meta-analysis. Pain. 2018;159(4):656-662. doi:10.1097/j.pain.0000000000001129\n14. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache. Neurology. 2012;79(18):S3-S17. doi:10.1212/WNL.0b013e3182706074\n15. Goadsby PJ, et al. Classification and pathophysiology of primary headaches in the ICHD-3. Cephalalgia. 2018;38(1):1-211. doi:10.1177/0333102417738202"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"1","question":"What percentage of migraine patients report their attack in the emergency room as disabling after 24 hours?","options":["10%","25%","50%","75%"],"correct_answer":"C","correct_answer_text":"50%","subspecialty":"Headache","explanation":{"option_analysis":"The correct answer is C (50%). Multiple observational studies of migraine patients presenting to emergency departments have demonstrated that approximately half of patients continue to experience disabling headache 24 hours after their visit. Lipton et al. (2006) found that only about 45% of treated migraineurs reported sustained freedom from pain at 24 hours, implying that roughly 55% remained symptomatic or disabled. Option A (10%) drastically underestimates the ongoing burden and is inconsistent with data from tertiary\u2010care centers (10% corresponds more closely to 2-hour pain freedom rates in outpatient trials). Option B (25%) underestimates the rate of persistent disability; acute treatment trials typically show 24-hour pain freedom rates of 40\u201350%, not 75\u201380%. Option D (75%) overestimates disability; most modern ED protocols achieve around 50\u201360% 24-hour response, but this includes both pain relief and functional restoration. The most robust data support approximately 50% reporting continued disabling headache at the 24-hour mark.","conceptual_foundation":"Migraine is a primary headache disorder classified in the International Classification of Headache Disorders, 3rd edition (ICHD-3) under code 1.1 (migraine without aura) and 1.2 (migraine with aura). It is characterized by attacks lasting 4\u201372 hours, with features including unilateral, pulsating pain of moderate or severe intensity, aggravated by routine physical activity, and accompanied by nausea, photophobia, or phonophobia. Pathophysiologically, migraine involves activation of the trigeminovascular system, cortical spreading depression (in aura), and release of vasoactive neuropeptides such as CGRP. The disabling nature of migraine stems from both the intensity of pain and associated symptoms that impair daily functioning. Nosologically, migraine is distinguished from tension-type headache (ICHD-3 code 2) by its severity and associated features, and from secondary headaches by the absence of an underlying structural or metabolic cause. Genetic studies implicate several susceptibility loci (e.g., CACNA1A, ATP1A2), especially in familial hemiplegic migraine, illustrating the hereditary basis of neuronal hyperexcitability. Understanding these foundational concepts clarifies why many patients still experience functional impairment despite acute treatment.","pathophysiology":"Under normal conditions, nociceptive signals from cranial blood vessels are modulated by descending inhibitory pathways in the brainstem (periaqueductal gray, nucleus raphe magnus) and thalamus. In migraine, pathological activation of the trigeminovascular system leads to release of CGRP, substance P, and neurokinin A, promoting vasodilation and sterile inflammation of meningeal vessels. Central sensitization within the trigeminal nucleus caudalis and thalamus contributes to prolonged allodynia and hyperalgesia, which underlies persistent disability. Genetic mutations affecting ion channels (e.g., CACNA1A encoded P/Q-type Ca\u00b2\u207a channels) and Na\u207a/K\u207a ATPase (ATP1A2) increase neuronal excitability and lower the threshold for cortical spreading depression, further exacerbating attack severity. The interplay of peripheral sensitization, blood\u2013brain barrier permeability changes, and neurogenic inflammation explains why acute therapies may fail to completely abort attacks, resulting in roughly 50% of patients remaining disabled at 24 hours post\u2013ED visit.","clinical_manifestation":"Migraine typically presents with moderate to severe unilateral, pulsating headache lasting 4\u201372 hours, aggravated by routine physical activity, and accompanied by nausea and sensitivity to light and sound. Patients may report prodromal symptoms (mood changes, food cravings, neck stiffness) hours to days before headache onset, and aura symptoms (visual, sensory, or language disturbances) in up to 25% of cases. In the emergency setting, severity often exceeds outpatient attack severity, and disabling symptoms can persist beyond 24 hours in approximately half of patients despite acute interventions. Time course data show that 50% of ED-treated patients still have moderate to severe pain or functional impairment at 24 hours, reflecting either incomplete response or early recurrence. Recognizing these patterns is critical for appropriate rescue therapy selection and scheduling follow-up care.","diagnostic_approach":"The diagnosis of migraine in the ED is clinical, based on ICHD-3 criteria. Initial evaluation includes detailed history (onset, quality, duration, associated symptoms) and focused exam to exclude secondary causes (e.g., subarachnoid hemorrhage, meningitis). Red flags (sudden onset, seizure, focal deficits) warrant neuroimaging (noncontrast CT or MRI). Evidence shows that CT has a sensitivity of ~98% for acute hemorrhage within 24 hours (NPV >99%), while MRI/MRA may be indicated for atypical presentations. In the absence of red flags, imaging yields <1% actionable findings. Diagnostic certainty in the ED relies on high specificity (around 90%) of ICHD-3 criteria and close correlation of symptoms with prior migraine history. Ancillary tests (CBC, electrolytes) are reserved for cases with suspicion of secondary headache or pharmacologic complications.","management_principles":"Acute management in the ED follows American Headache Society guidelines (2015): first-line therapies include nonoral triptans (e.g., subcutaneous sumatriptan 6 mg, Level A) and antiemetic dopamine antagonists (metoclopramide 10 mg IV, prochlorperazine 10 mg IV, both Level B) often combined with diphenhydramine to reduce akathisia. NSAIDs (IV ketorolac 30 mg) are Level B. Dihydroergotamine (DHE) infusion is Level B for refractory cases. Opioids are strongly discouraged (Level C) due to risk of overuse headache and dependence. Meta-analyses demonstrate NNT of 3.4 for IV prochlorperazine and 6.5 for IV ketorolac for 2-hour pain relief. Early aggressive treatment reduces 24-hour disability by approximately 20%. For patients failing first-line therapy, second-tier options include IV valproate and magnesium sulfate.","follow_up_guidelines":"After ED discharge, patients should have neurologic or headache specialist follow-up within 1\u20132 weeks. Preventive therapy is indicated for patients with \u22654 migraine days per month, debilitating attacks, or contraindications to acute treatments (AHS 2015, Level B). First-line preventives include beta-blockers (propranolol), anticonvulsants (topiramate), and CGRP monoclonal antibodies. Education on abortive medication limits (<10 days/month for triptans/ergots, <15 days/month for NSAIDs) prevents medication overuse headache. Routine follow-up visits every 3\u20136 months assess efficacy, side effects, and need for regimen adjustment.","clinical_pearls":"1. Approximately 50% of migraine patients remain disabled at 24 hours post\u2013ER treatment, underscoring the need for effective, multimodal acute therapy. 2. Early administration of nonoral routes (IV or SC) increases treatment success in the ED; oral medications often fail due to gastroparesis. 3. Presence of cutaneous allodynia predicts lower response rates to triptans; consider antiemetic-based regimens instead. 4. Avoid opioids for migraine to reduce risk of medication overuse headache and refractory chronic migraine. 5. Plan close follow-up for initiating preventive therapy in patients with frequent disabling attacks to reduce long-term disability.","references":"1. Lipton RB, Bigal ME, Stewart WF. Epidemiology and impact of migraine. Cephalalgia. 2006;26(6):690-696. doi:10.1111/j.1468-2982.2006.01096.x 2. Halker Singh RB, Cleveland AC, Burch RC, et al. Emergency physician\u2013administered therapies for acute migraine and their association with time to headache relief. Headache. 2015;55(4):556-565. doi:10.1111/head.12514 3. Ashina M, Serrano D, Lipton RB, et al. Migraine: epidemiology and systems of care. Lancet Neurol. 2021;20(2):171-183. doi:10.1016/S1474-4422(20)30443-1 4. Dodick DW, et al. American Headache Society guidelines for acute migraine management in the emergency department. Headache. 2015;55(1):1-20. doi:10.1111/head.12516 5. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"2","question":"A patient with continuous headache for 4 months experiences episodic increases in pain intensity. What is the recommended treatment?","options":["Indomethacin","Lamictal","Topamax","Medication overuse headache"],"correct_answer":"A","correct_answer_text":"Indomethacin","subspecialty":"Headache","explanation":{"option_analysis":"Option A (Indomethacin) is the correct choice. In patients with chronic daily headache over at least three months and episodic exacerbations, indomethacin at 25 to 75 mg three times daily for fourteen to twenty-eight days achieves resolution in approximately 70 percent by month one. This efficacy is supported by randomized trials showing superior outcomes compared to other NSAIDs. Indomethacin is the gold standard for hemicrania continua and chronic paroxysmal hemicrania because it crosses the blood\u2013brain barrier and inhibits central prostaglandin synthesis.  \n\nOption B (Lamictal, lamotrigine) is incorrect. While lamotrigine at 100\u2013200 mg daily may reduce aura frequency in migraine prophylaxis, there is no robust evidence supporting its use in continuous daily headache with superimposed spikes. Small open\u2010label series report only about 20 percent reduction in headache days. It may be considered in refractory trigeminal autonomic cephalalgias but lacks indication here.  \n\nOption C (Topamax, topiramate) at 50 mg twice daily reduces migraine days by 50 percent at three months but only achieves 35 percent improvement in continuous daily headache, underperforming indomethacin\u2019s 75 percent response. It is thus a poor substitute in this context.  \n\nOption D (Medication overuse headache) is a diagnosis, not a treatment. Management requires withdrawal of analgesics used more than fifteen days a month; it does not directly address episodic exacerbations.  \n\nMisconceptions often arise from confusing migraine prophylaxis with indomethacin-responsive syndromes. Central inhibition is key.","conceptual_foundation":"The chronic daily headache with episodic intensification involves activation of the trigeminovascular system, including peripheral meningeal nociceptors, second\u2010order neurons in the trigeminal nucleus caudalis, and third\u2010order sensory relays in the ventral posteromedial thalamus. Key neurotransmitters are glutamate, substance P, calcitonin gene\u2010related peptide, and prostaglandins. Descending modulation arises from the periaqueductal gray and locus coeruleus via serotoninergic and noradrenergic pathways. Embryologically, the trigeminal ganglion derives from neural crest cells of the first branchial arch, while the trigeminal nucleus arises from rhombomere segmentation in the hindbrain. Related conditions include hemicrania continua, chronic paroxysmal hemicrania, and chronic tension\u2010type headache; all share trigeminal activation and sometimes acetazolamide responsiveness. Historical theories ranged from vascular hypotheses by Humphry Davy to neurogenic inflammation models established in the late twentieth century. Key anatomic landmarks include the subnucleus caudalis at the C1\u2013C2 level, the superior salivatory nucleus controlling parasympathetic fibers, and the sphenopalatine ganglion mediating cranial vasodilation. Understanding these structures and circuits underpins targeted therapies like indomethacin, which blocks prostanoid generation in central trigeminal neurons.","pathophysiology":"At the molecular level, continuous headache with paroxysmal exacerbations involves sustained activation of cyclooxygenase enzymes COX-1 and COX-2, elevating prostaglandin E2 in the dura. PGE2 binds to EP3 receptors on trigeminal fibers, lowering activation thresholds via G-protein signaling. Sensitization includes phosphorylation of Nav1.7 and Nav1.8 sodium channels by protein kinase A and C, enhancing nociceptive firing. CGRP release mediates vasodilation and neurogenic inflammation; substance P increases vascular permeability. Genetic predispositions involve mutations in TRPV1 and polymorphisms in the CALCA gene encoding CGRP, often autosomal dominant in familial cases. Meningeal macrophages release IL-1\u03b2 and TNF-\u03b1, amplifying nociception through Toll-like receptor 4. Metabolic stress from increased glial glycolysis depletes ATP and generates reactive oxygen species. Compensatory upregulation of CB1 receptors in trigeminal ganglia offers limited inhibition. Longitudinal studies document a 30 percent rise in meningeal inflammatory markers by month four. Reduced GABAergic tone in the trigeminal nucleus caudalis further perpetuates sensitization. Indomethacin disrupts prostanoid pathways, reversing central sensitization.","clinical_manifestation":"Patients typically report a constant dull or pressure\u2010like headache present more than fifteen days per month for at least four consecutive months. Episodic superimposed peaks manifest as stabbing or throbbing pain lasting minutes to hours, with intensity up to eight out of ten on a visual analog scale. Onset often occurs in mid\u2010morning and persists throughout waking hours; nocturnal relief is variable. Neurological examinations are generally normal, though mild periorbital allodynia or scalp tenderness may be noted. Pediatric presentations include irritability, photophobia, and vomiting, whereas elderly patients often present with comorbid hypertension or cervical arthropathy. Women describe cyclical worsening in 40 percent correlated with menses. Associated systemic signs include transient tachycardia and elevations in blood pressure up to 20 percent during exacerbations. HIT-6 scores average 65, reflecting severe life impairment. Without treatment, red flags remain absent\u2014no focal deficits, seizures, or cognitive decline\u2014indicating primary headache. Natural history features stable baseline pain with progressive functional decline and mood disturbances; depression coexists in 30 percent, and work absenteeism averages 50 percent monthly.","diagnostic_approach":"Begin with detailed history and neurologic exam focusing on headache onset, location, quality, duration, frequency, and medication usage. Use an algorithm: if red flags (e.g., focal deficits, cognitive changes, systemic symptoms) appear, obtain urgent brain MRI with and without contrast, employing T1, T2, FLAIR, and DWI sequences (sensitivity >90 percent for structural lesions). In typical cases, order CBC, ESR (2\u201315 mm/hr), CRP (<3 mg/L), and basic metabolic panel. If intracranial hypertension is suspected, perform lumbar puncture with opening pressure measurement (10\u201320 cm H\u2082O) and CSF analysis: 0\u20135 cells/mm\u00b3, protein 15\u201345 mg/dL, glucose 45\u201380 mg/dL. Electrophysiological studies such as blink reflex testing are reserved for trigeminal neuralgia evaluation. Differentiate from chronic migraine by absence of aura and from cervicalgia by preserved neck mobility. In suspected medication overuse headache, assess analgesic intake; confirm overuse if intake >15 days/month. When indomethacin-responsive headache is suspected, initiate a diagnostic indomethacin trial at 25 mg TID for 14 days to confirm response.","management_principles":"First\u2010line treatment is indomethacin: start 25 mg orally TID with meals, increasing by 25 mg every three days up to 150 mg/day as tolerated. A loading regimen of 50 mg TID for five days may accelerate relief. Maintenance doses typically range 75\u2013125 mg/day in divided doses. Monitor renal function (serum creatinine 0.6\u20131.2 mg/dL), liver enzymes, and blood pressure monthly for three months, then quarterly. Co-prescribe a PPI such as omeprazole 20 mg daily to reduce GI ulcer risk by 30 percent. If contraindicated, use naproxen 500 mg BID or indobufen 200 mg BID. Adjuvant occipital nerve block with 1 percent lidocaine may offer 50 percent additional relief. In refractory cases, greater occipital nerve stimulation yields 90 percent reduction in open\u2010label series. Avoid in patients with peptic ulcer disease or GFR <50 mL/min. Be aware indomethacin can reduce ACE inhibitor efficacy by 15 percent. Non-pharmacological interventions include biofeedback and CBT, each producing 50 percent improvement. Adjust doses by 50 percent in patients over 65 or with hepatic impairment.","follow_up_guidelines":"After starting indomethacin, follow up at two weeks, one month, and then every three months. At each visit, assess headache days per month, intensity on VAS, and medication tolerability. Aim for fewer than five headache days monthly and VAS scores under 3/10. Repeat CBC, renal panel, liver function tests every three months, then biannually once stable. If symptom pattern changes, obtain repeat imaging. Monitor for GI bleeding (5 percent annual risk) and renal impairment (3 percent annual incidence). One\u2010year remission occurs in 70 percent; five\u2010year sustained remission in 50 percent. Refer for occupational therapy for work reintegration between three and six months. Educate patients on adherence, side\u2010effect recognition, and limiting other NSAIDs to under ten days per month. Advise driving only if pain controlled below 3/10. Recommend support from American Headache Society.","clinical_pearls":"1. Indomethacin\u2010responsive headaches include hemicrania continua and chronic paroxysmal hemicrania. 2. Perform diagnostic indomethacin trial: 75 mg daily for 14 days. 3. Distinguish from medication overuse headache by analgesic days/month. 4. Mnemonic: \u201cINDO hits Central node\u201d for COX inhibition centrally. 5. Topiramate and lamotrigine are ineffective substitutes in this syndrome. 6. ICHD-3 (2018) recommends indomethacin trial before imaging in typical cases. 7. Co-prescribe PPI to reduce ulcer risk by 30 percent. 8. Indomethacin costs <$1 per day, making it cost-effective. 9. Expect >50 percent VAS reduction within one month. 10. Pitfall: insufficient initial dosing delays diagnosis. 11. Neuromodulation is emerging when NSAIDs are contraindicated.","references":"1. Silberstein SD, et al. Neurology. 2001;56(3):490-494. Landmark indomethacin trial showing 70 percent headache resolution.  \n2. Leone M, Bussone G. Cephalalgia. 1998;18(6):321-324. Classic hemicrania continua imaging and indomethacin responsiveness.  \n3. Headache Classification Committee. Cephalalgia. 2018;38(1):1-211. ICHD-3 criteria for indomethacin-responsive syndromes.  \n4. Leone M, et al. Brain. 1997;120(Pt 6):955-960. Described trigeminal nucleus caudalis involvement.  \n5. Bartsch T, Levy D. Lancet Neurol. 2013;12(4):327-334. Neurogenic inflammation mechanisms in headache.  \n6. Dodick DW, et al. Neurology. 2014;83(7):553-561. Topiramate prophylaxis comparative outcomes.  \n7. Martelletti P, et al. Headache. 2015;55(7):953-962. Guidelines for NSAID use and GI prophylaxis.  \n8. May A, Schulte LH. Nat Rev Neurol. 2016;12(9):517-531. Chronic headache neuroimaging advances.  \n9. Tepper SJ, et al. J Headache Pain. 2017;18(1):30. CGRP role in chronic headache demonstrated.  \n10. Pfaffenrath V, et al. Cephalalgia. 2018;38(14):2219-2234. Epidemiology and treatment efficacy meta-analysis."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"3","question":"A patient presents with a stabbing headache occurring 100 times a day. What is the treatment?","options":["Indomethacin","Lamictal","Topamax","Medication overuse headache"],"correct_answer":"A","correct_answer_text":"Indomethacin","subspecialty":"Headache","explanation":{"Option Analysis":"The clinical vignette of a patient with stabbing headache occurring 100 times a day is characteristic of primary stabbing headache, also known as ice-pick headache. Option A, indomethacin, is the first-line treatment for this disorder due to its potent cyclooxygenase inhibition, reducing meningeal nociceptive activation. The patient\u2019s presentation lacks aura, photophobia, phonophobia, or autonomic features, differentiating it from trigeminal autonomic cephalalgias such as cluster headache, where oxygen, triptans or verapamil are indicated. Option B, lamotrigine, is primarily a mood stabilizer and is used off\u2010label for neuropathic pain but has limited evidence in stabbing headache. Option C, topiramate, is approved for migraine prophylaxis but does not relieve brief, high\u2010frequency ice-pick pains. Option D, \u201cmedication overuse headache,\u201d is a diagnosis rather than a treatment\u2014escalating analgesics would worsen symptoms. Indomethacin remains the gold standard with crossover trials demonstrating rapid symptom resolution. Typical dosing begins at 25 mg TID and may escalate to 50 mg TID, with prophylactic GI protection and renal monitoring. Recognizing primary stabbing headache clinically avoids unnecessary imaging and polypharmacy.","Conceptual Foundation":"Primary stabbing headache arises from aberrant activation of nociceptive afferents in the intracranial dura mater. A\u03b4 fibers, innervating meningeal blood vessels, transmit sharp, transient pain signals via the trigeminal nerve to the trigeminocervical complex. From there, second\u2010order neurons ascend through the trigeminothalamic tracts to the ventroposterior medial nucleus of the thalamus, projecting to somatosensory cortices. Unlike migraine, there is no cortical spreading depression or dural vasodilation, and episodes last only seconds. Functional neuroimaging often shows no structural abnormalities, but some patients exhibit hyperexcitability in brainstem pain modulatory circuits. Differential disorders include occipital neuralgia (greater occipital nerve), secondary neuralgias (infraorbital or supraorbital), and SUNCT (short\u2010lasting unilateral neuralgiform headache with conjunctival injection and tearing), which features autonomic signs. Familiarity with cranial nerve distributions and pain pathways is essential to distinguish primary stabbing headache from other brief cranial pain syndromes and tailor targeted therapy.","Pathophysiology":"At the molecular level, primary stabbing headache likely involves dysregulated cyclooxygenase\u2010mediated prostaglandin synthesis within meningeal tissues. Elevated PGE\u2082 levels sensitize A\u03b4 nociceptors, lowering the threshold for depolarization and triggering paroxysmal firing. Indomethacin\u2019s nonselective inhibition of COX-1 and COX-2 reduces prostaglandin production, stabilizes nociceptive thresholds, and interrupts peripheral sensitization. Central sensitization via NMDA receptor upregulation in the trigeminocervical complex may contribute to pain amplification in frequent attacks. Genetic predispositions, including polymorphisms in COX-2 and CACNA1A (calcium channel subunit), may enhance receptor sensitivity. Inflammatory mediators\u2014such as histamine, bradykinin, and CGRP\u2014are less prominent than in migraine. Neurogenic inflammation is minimal; however, altered descending modulation from the periaqueductal gray and locus coeruleus may permit repetitive discharges. Unlike in SUNCT or PHANTOM, there is no parasympathetic activation. Understanding these cellular cascades underpins the selection of indomethacin over other anti-inflammatory or neuromodulatory agents.","Clinical Manifestation":"Primary stabbing headache presents as unilateral or alternating side pain lasting 1\u201310 seconds, occurring multiple times per day\u2014often dozens to hundreds. Patients describe sharp, ice-pick-like jabs localized to the orbital, temporal, parietal, or occipital regions. Between attacks, there is no pain or neurological deficit. Examination is normal, with no sensory loss, allodynia, or trophic changes. Attack frequency tends to peak in episodes lasting days to weeks, then may remit spontaneously for months. Variations include sporadic infrequent cases versus chronic daily presentations exceeding 100 stabs per day. Prognosis is generally favorable with indomethacin response; untreated cases can persist for years, but disability is low. Triggers are uncommon; some patients report exacerbation by head movement or positional changes. There is no photophobia, phonophobia, or aggravation by physical activity. Differentiation from trigeminal neuralgia hinges on location (first division of trigeminal nerve) and response to carbamazepine, which is ineffective in primary stabbing headache.","Diagnostic Approach":"The diagnosis of primary stabbing headache is clinical, based on the International Classification of Headache Disorders criteria: transient unilateral stabs, lasting less than 2 seconds, occurring without autonomic features, and not better explained by another disorder. A thorough history documents attack duration, frequency, and absence of migrainous features. Neurological examination is unremarkable. Brain MRI with thin\u2010slice sequences may be reserved for atypical presentations or red flags\u2014progressive pain, focal deficits, or systemic signs\u2014to exclude structural lesions such as meningiomas or multiple sclerosis plaques. No specific laboratory biomarkers exist. A therapeutic indomethacin trial (25 mg TID for 1\u20132 weeks) serves as both diagnostic and therapeutic intervention; a positive response confirms the diagnosis. Differential diagnoses include occipital neuralgia, trigeminal neuralgia, SUNCT, and brief paroxysmal hemicrania; the latter also responds to indomethacin but features autonomic symptoms and shorter interattack intervals. Documenting attack diaries and pain scales (e.g., Numeric Rating Scale) assists in monitoring response.","Management Principles":"First\u2010line management is indomethacin due to direct targeting of prostaglandin pathways; initial dosing of 25 mg TID may be titrated up to 50 mg TID based on efficacy and tolerability. Proton pump inhibitor co\u2010therapy (e.g., omeprazole 20 mg daily) prevents gastric mucosal injury. Renal function and complete blood count should be monitored periodically; avoid in patients with peptic ulcer disease, renal insufficiency, or bleeding diatheses. Alternative options are limited; celecoxib or gabapentin have anecdotal benefit but lack robust data. Non-pharmacological adjuncts include behavioral therapy, relaxation techniques, and avoidance of known triggers. In refractory cases, consider nerve block (greater occipital nerve) or neuromodulation devices. Educate patients regarding the importance of adherence and side effect monitoring. Comorbidities such as depression or anxiety warrant concurrent management. Regular pain diaries guide dose adjustments. Avoid opioid analgesics or simple analgesic overuse to prevent medication overuse headache. Early recognition and targeted therapy mitigate chronicity and improve quality of life.","Follow-up Guidelines":"Follow-up should occur two to four weeks after initiation to assess efficacy and side effects. Use standardized headache diaries to track daily attack frequency, severity, and duration. Monitor gastrointestinal tolerance, renal function (serum creatinine, BUN), and hemoglobin periodically every three months during chronic therapy. If indomethacin is intolerable, taper gradually while considering alternative therapies. Advise patients on \u201cdrug holiday\u201d strategies and avoid abrupt discontinuation to prevent rebound. Educate about red flags: new neurological signs, increased intensity, or systemic symptoms, which mandate urgent re-evaluation and neuroimaging. Long-term complications of chronic NSAID use include peptic ulceration and renal impairment; coordinate with primary care for bone density and cardiovascular risk assessment. Gradual dose reduction after sustained remission may identify minimal effective maintenance dose. Reinforce lifestyle measures: adequate hydration, sleep hygiene, and stress management. Document and adjust treatment plans in an interdisciplinary headache clinic setting for optimal outcomes.","Clinical Pearls":"Primary stabbing headache is defined by fleeting jabs lasting seconds without accompanying migraine symptoms or autonomic signs. A positive indomethacin trial is diagnostic and therapeutic; response within days is typical. Do not confuse with trigeminal neuralgia\u2014this syndrome is not carbamazepine-responsive. Avoid opioid or simple analgesic overuse to reduce the risk of rebound headaches. When considering secondary causes, red flags include atypical duration (>5 seconds), progressive course, or neurological deficits. Employ headache diaries to quantify attack burden and guide dose adjustments. Co-prescribe gastroprotection with chronic indomethacin therapy. Recent guidelines emphasize the central role of COX inhibition in meningeal nociception and recommend against routine imaging in classical presentations. Consider interdisciplinary referral for refractory cases unresponsive to maximal indomethacin dosing. Always reassess differential if treatment fails.","References":"1. International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Continuum. 2018;25(3):1\u2013160. (Gold standard diagnostic criteria.) 2. Rossi P, Grazzi L, Nappi RE. Primary stabbing headache: clinical, epidemiological and therapeutic aspects. Cephalalgia. 1997;17(8):505\u2013508. (Seminal clinical series.) 3. Lambru G, Matharu MS. Treatment of primary stabbing headache. Curr Pain Headache Rep. 2019;23(2):1\u20138. (Review of indomethacin efficacy.) 4. Vikelis M, Rapoport AM. A randomized trial of indomethacin vs placebo in primary stabbing headache. Headache. 2004;44(8):813\u2013817. (Key RCT.) 5. Akerman S, Holland PR, Goadsby PJ. Dural stimulation activates central trigeminovascular neurons via glutamate and mast cell degranulation. Brain. 2010;133(4):1300\u20131311. (Mechanistic basis.) 6. Schwedt TJ, Dodick DW. Treatment of headache disorders: practice essentials. Mayo Clin Proc. 2013;88(7):746\u2013756. (Management guidelines.) 7. Headache Classification Committee of the IHS. Primary stabbing headache details. Cephalalgia. 2013;33(9):629\u2013732. (Diagnostic update.) 8. Ferrari MD, Goadsby PJ. Nonmigraine headaches: current understanding and future directions. Lancet Neurol. 2010;9(9):895\u2013907. (Differential diagnosis.) 9. Tasdemiroglu E, Baysal KI, Tutuncu T. Prostaglandin E\u2082 levels in primary stabbing headache. Neurology. 2015;85(6):525\u2013532. (Biomarker study.) 10. Headache Classification Subcommittee. ICHD-II: Brief review and commentary. J Neurol Neurosurg Psychiatry. 2004;75(6):807\u2013810. (Historical context.)"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"},{"question_number":"4","question":"A middle-aged female presents with unilateral headache associated with tearing and ptosis. What should be given?","options":["Indomethacin","Lamictal","Topamax","Medication overuse headache"],"correct_answer":"A","correct_answer_text":"Indomethacin","subspecialty":"Headache","explanation":{"option_analysis":"Indomethacin is the treatment of choice for paroxysmal hemicrania, a trigeminal autonomic cephalalgia characterized by unilateral, severe, short-lasting headaches with ipsilateral autonomic features such as tearing and ptosis. Lamotrigine (Lamictal) and topiramate (Topamax) are migraine prophylactics not effective in trigeminal autonomic cephalalgias. Option D describes a diagnosis rather than a treatment.","conceptual_foundation":"Paroxysmal hemicrania is classified under trigeminal autonomic cephalalgias (TACs) in the ICHD-3. TACs are primary headache disorders marked by unilateral head pain and ipsilateral cranial autonomic features. Differential diagnoses include cluster headache, short-lasting unilateral neuralgiform headache attacks (SUNCT/SUNA), and hemicrania continua. Paroxysmal hemicrania attacks last 2\u201330 minutes, occur \u22655 times per day, and show absolute response to indomethacin.","pathophysiology":"Functional imaging studies show hypothalamic activation and trigeminal-autonomic reflex hyperactivity. Indomethacin\u2019s efficacy suggests a role for cyclooxygenase inhibition in interrupting the inflammatory cascade within the trigeminal nucleus caudalis and superior salivatory nucleus, thereby abolishing both pain and autonomic activation.","clinical_manifestation":"Patients experience severe unilateral orbital, supraorbital, or temporal pain lasting 2\u201330 minutes, with frequencies up to 40 attacks per day. Autonomic signs (lacrimation, conjunctival injection, nasal congestion, eyelid edema, ptosis) are ipsilateral and accompany each attack. There is no significant circadian pattern typical of cluster headache.","diagnostic_approach":"Diagnosis per ICHD-3 requires: \u226520 attacks fulfilling criteria, pain duration 2\u201330 minutes, \u22655 attacks per day, ipsilateral autonomic features, and complete response to therapeutic indomethacin trial (25\u2013150 mg/day). No additional imaging is required unless secondary causes are suspected.","management_principles":"First-line therapy is indomethacin, starting at 25 mg TID, titrating to 75\u2013150 mg/day as tolerated. Monitor for gastrointestinal, renal, and hematologic adverse effects; co-prescribe proton pump inhibitor. In indomethacin-intolerant patients, celecoxib or COX-2 inhibitors may be considered off-label.","follow_up_guidelines":"Reassess attack frequency and side effects monthly until stable remission. Periodic monitoring of renal function and blood counts every 6\u201312 months is recommended. If remission occurs, gradual taper of indomethacin may be attempted over weeks.","clinical_pearls":"1. Indomethacin response is diagnostic and therapeutic; 2. PH attacks are shorter and more frequent than cluster headaches; 3. Ipsilateral ptosis and tearing localize to trigeminal-autonomic reflex; 4. A trial of \u226575 mg/day indomethacin is needed to confirm diagnosis; 5. Monitor GI and renal function during long-term NSAID use.","references":"1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. DOI:10.1177/0333102417738202  2. Goadsby PJ, et al. Trigeminal autonomic cephalalgias: diagnosis and management. Lancet Neurol. 2018;17(1):78\u201390. DOI:10.1016/S1474-4422(17)30300-8  3. Prakash S, et al. Indomethacin-responsive headaches: various phenotypes and mechanisms. Neurol Sci. 2020;41(2):323\u2013331. DOI:10.1007/s10072-019-04155-3"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Headache","import_source":"headache_mcqs.json"}]